Video

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Results from the phase III POLO trial showed a significant improvement in progression-free survival with olaparib (Lynparza) maintenance therapy in patients with advanced germline BRCA-mutated disease who did not progress on platinum-based chemotherapy. As such, the National Comprehensive Cancer Network guidelines recommend to test patients with advanced metastatic pancreatic cancer for BRCA1/2 mutations.

With these recommendations in place, genetic testing is becoming more widespread in pancreatic cancer. However, the role of testing for somatic mutations is not as well defined, says Richards. Additionally, several challenges have made testing difficult to adopt routinely, including the availability of tissue and cost of mutational analysis, concludes Richards.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS